Hims & Hers bets FDA shortage rule on $199 GLP-1s; channel closes, stock swings

Hims & Hers is a direct-to-consumer telehealth platform (NYSE: HIMS) selling prescriptions for erectile dysfunction, hair loss, skin care and weight loss; from May 2024 it added compounded semaglutide injections at $199/month, versus roughly $1,000/month for branded Wegovy.

That the FDA shortage list would keep compounding legal long enough for a $199 copycat GLP-1 to become the engine of its weight-loss business — until the shortage ended.

Hims was founded in 2017 by Andrew Dudum and went public via SPAC in January 2021. It launched a weight-loss program in December 2023, then on May 20 2024 announced compounded semaglutide injections — the active ingredient in Novo Nordisk's Ozempic and Wegovy, which had been in shortage since 2022 — at $199/month. Shares jumped 27% that day.

The product scaled fast: GLP-1 offerings generated over $225M of revenue in 2024 and drove the company's total revenue to $1.5B. The regulatory ground then shifted twice. On Oct 2 2024 the FDA declared the shortage of Lilly's tirzepatide resolved, and on Feb 21 2025 it declared semaglutide resolved as well — Hims shares fell more than 25% that day. On its Feb 24 2025 earnings call the company said it would likely stop offering compounded semaglutide after Q1; Q4 2024 revenue was $481M (+95% YoY) but the stock fell 22% the next day on margin pressure and the pivot. Novo Nordisk then ended a commercial collaboration with Hims in June 2025, sending shares down 31%. Hims pivoted to oral medications and branded injectables, and full-year 2025 revenue still reached $2.35B.

The company is still running and growing — 2.5M subscribers and $2.35B revenue in 2025 — but the compounded-GLP-1 channel that powered the boom is closed. On the Q4 2025 call (Feb 23 2026) CEO Andrew Dudum acknowledged the 'draconian scenario' of compounded GLP-1s disappearing, and 2026 guidance of $2.7-2.9B excludes semaglutide contributions.

The FDA shortage list was the whole wedge: no shortage, no legal right to compound a copy, no $199 product.

Pricing at a fifth of branded cost converted a regulatory technicality into a mass-market consumer decision and a 27% stock pop.

The same agency action that opened the channel (listing a shortage) could close it, and did — first tirzepatide in Oct 2024, then semaglutide in Feb 2025.

Diversifying the funnel (oral meds, other conditions) is what let the company keep growing after the flagship product was regulated out of existence.

A business built on a regulatory exemption is a bet on the regulator's timeline: the same shortage list that legalized the product could be emptied, and the exit ramp was never in Hims' control.

As of 2026-09-02 Hims & Hers is live and growing: 2.5M subscribers and $2.35B revenue for 2025, with 2026 guidance of $2.7-2.9B excluding compounded semaglutide. The FDA's Feb 2025 resolution gave compounders 60-90 days to wind down, and later rules kept tightening; in May 2026 Hims said it would stop its compounded semaglutide pill after an FDA crackdown. The company now leans on oral weight-loss meds, branded injectables and partnerships (including renewed talks with Novo Nordisk), while investors keep pricing each FDA statement into the stock.